Coagulation factor XI as a novel target for antithrombotic treatment

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 11, 2010, Pages 2349-2357

  Lowenberg E C ^a   Meijers, J C M ^a   Monia, B P ^b   Levi, M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense therapy; Coagulation factor XI; FXI deficiency; FXI inhibition; Intrinsic pathway; Thrombosis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTISENSE OLIGONUCLEOTIDE; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 11A; CLOPIDOGREL; D DIMER; ENOXAPARIN; HEPARIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTISENSE THERAPY; ARTERY OCCLUSION; ARTERY THROMBOSIS; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FIBRINOLYSIS; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; HEART CATHETERIZATION; HEART INFARCTION; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; INJURY SEVERITY; MENORRHAGIA; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PARTIAL THROMBOPLASTIN TIME; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; REPERFUSION INJURY; REVIEW; STROKE; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS;

ANIMALS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XI; FACTOR XI DEFICIENCY; FIBRINOLYTIC AGENTS; HEMOSTASIS; HUMANS; MICE; MODELS, BIOLOGICAL; OLIGONUCLEOTIDES, ANTISENSE; REPERFUSION INJURY; THROMBOEMBOLISM; THROMBOSIS; WARFARIN;

EID: 78149254900     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04031.x     Document Type: Review

References (49)

1. Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964; 202: 498-9.
2. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145: 1310-2.
3. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266: 7353-8.
4. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-12.
5. Colman RW, Scott CF. When and where is factor XI activated by thrombin? Blood 1996; 87: 2089.
6. Pedicord DL, Seiffert D, Blat Y. Feedback activation of factor XI by thrombin does not occur in plasma. Proc Natl Acad Sci USA 2007; 104: 12855-60.
7. Wielders SJ, Beguin S, Hemker HC, Lindhout T. Factor XI-dependent reciprocal thrombin generation consolidates blood coagulation when tissue factor is not available. Arterioscler Thromb Vasc Biol 2004; 24: 1138-42.
8. Kravtsov DV, Matafonov A, Tucker EI, Sun MF, Walsh PN, Gruber A, Gailani D. Factor XI contributes to thrombin generation in the absence of factor XII. Blood 2009; 114: 452-8.
9. Meijers JC. Feedback controversy stops here. Blood 2009; 114: 235.
10. Von Dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86: 3035-42.
11. Von Dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
12. Rosenthal RL, Dreskin OH, Rosenthal N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med 1953; 82: 171-4.
13. Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 1991; 325: 153-8.
14. Shpilberg O, Peretz H, Zivelin A, Yatuv R, Chetrit A, Kulka T, Stern C, Weiss E, Seligsohn U. One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood 1995; 85: 429-32.
15. Seligsohn U, Modan M. Definition of the population at risk of bleeding due to factor XI deficiency in Ashkenazic Jews and the value of activated partial thromboplastin time in its detection. Isr J Med Sci 1981; 17: 413-5.
16. Bolton-Maggs PH, YoungWan-Yin B, Mccraw AH, Slack J, Kernoff PB. Inheritance and bleeding in factor XI deficiency. Br J Haematol 1988; 69: 521-8.
17. Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. Definition of the bleeding tendency in factor XI-deficient kindreds - a clinical and laboratory study. Thromb Haemost 1995; 73: 194-202.
18. Tavori S, Brenner B, Tatarsky I. The effect of combined factor XI deficiency with von Willebrand factor abnormalities on haemorrhagic diathesis. Thromb Haemost 1990; 63: 36-8.
19. Gomez K, Bolton-Maggs P. Factor XI deficiency. Haemophilia 2008; 14: 1183-9.
20. Girolami A, Ruzzon E, Tezza F, Scandellari R, Vettore S, Girolami B. Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review. Haemophilia 2006; 12: 345-51.
21. Salomon O, Steinberg DM, Dardik R, Rosenberg N, Zivelin A, Tamarin I, Ravid B, Berliner S, Seligsohn U. Inherited factor XI deficiency confers no protection against acute myocardial infarction. J Thromb Haemost 2003; 1: 658-61.
22. Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111: 4113-7.
23. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342: 696-701.
24. Libourel EJ, Bank I, Meinardi JR, Volkers CP, Hamulyak K, Middeldorp S, Koopman MM, Van Pampus EC, Prins MH, Buller HR, Van Der Meer J. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica 2002; 87: 1068-73.
25. Lijfering WM, Christiansen SC, Rosendaal FR, Cannegieter SC. Contribution of high factor VIII, IX and XI to the risk of recurrent venous thrombosis in factor V Leiden carriers. J Thromb Haemost 2009; 7: 1944-6.
26. Lijfering WM, Brouwer JL, Veeger NJ, Bank I, Coppens M, Middeldorp S, Hamulyak K, Prins MH, Buller HR, Van Der Meer J. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009; 113: 5314-22.
27. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 2006; 108: 4045-51.
28. Merlo C, Wuillemin WA, Redondo M, Furlan M, Sulzer I, Kremer-Hovinga J, Binder BR, Lammle B. Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. Atherosclerosis 2002; 161: 261-7.
29. Tanis B, Algra A, Van Der Graaf Y, Helmerhorst F, Rosendaal F. Procoagulant factors and the risk of myocardial infarction in young women. Eur J Haematol 2006; 77: 67-73.
30. Berliner JI, Rybicki AC, Kaplan RC, Monrad ES, Freeman R, Billett HH. Elevated levels of Factor XI are associated with cardiovascular disease in women. Thromb Res 2002; 107: 55-60.
31. Yang DT, Flanders MM, Kim H, Rodgers GM. Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events. Am J Clin Pathol 2006; 126: 411-5.
32. Gailani D, Lasky NM, Broze GJ Jr. A murine model of factor XI deficiency. Blood Coagul Fibrinolysis 1997; 8: 134-44.
33. Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb Haemost 2002; 87: 774-6.
34. Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu MY, Smith PL, Seiffert DA, Schumacher WA, Ogletree ML, Gailani D. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 2005; 3: 695-702.
35. Regan Baird T, Gailani D, Furie B, Furie BC. Factor XI deficient mice have reduced platelet accumulation and fibrin deposition after laser injury. ASH Annual Meeting Abstracts 2004; 104: 218.
36. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-81.
37. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, Renne C, Gailani D, Nieswandt B, Renne T. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203: 513-8.
38. Gruber A, Hanson SR. Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood 2003; 102: 953-5.
39. Yamashita A, Nishihira K, Kitazawa T, Yoshihashi K, Soeda T, Esaki K, Imamura T, Hattori K, Asada Y. Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery. J Thromb Haemost 2006; 4: 1496-501.
40. Schumacher WA, Seiler SE, Steinbacher TE, Stewart AB, Bostwick JS, Hartl KS, Liu EC, Ogletree ML. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. Eur J Pharmacol 2007; 570: 167-74.
41. Tucker EI, Marzec UM, White TC, Hurst S, Rugonyi S, Mccarty OJ, Gailani D, Gruber A, Hanson SR. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood 2009; 113: 936-44.
42. Minnema MC, Friederich PW, Levi M, Von Dem Borne PA, Mosnier LO, Meijers JC, Biemond BJ, Hack CE, Bouma BN, Ten CH. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101: 10-4.
43. Wang X, Smith PL, Hsu MY, Gailani D, Schumacher WA, Ogletree ML, Seiffert DA. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost 2006; 4: 1982-8.
44. Lin J, Deng H, Jin L, Pandey P, Quinn J, Cantin S, Rynkiewicz MJ, Gorga JC, Bibbins F, Celatka CA, Nagafuji P, Bannister TD, Meyers HV, Babine RE, Hayward NJ, Weaver D, Benjamin H, Stassen F, Bdel-Meguid SS, Strickler JE. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants. J Med Chem 2006; 49: 7781-91.
45. Crooke ST. Progress in antisense technology. Annu Rev Med 2004; 55: 61-95.
46. Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, Crooke RM. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114: 1729-35.
47. Hong Z, Löwenberg EC, Crosby JR, Macleod R, Zhao C, Gao D, Black C, Meijers JCM, Stroes ES, Levi M, Monia BP. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010; in press.
48. Butler M, Mckay RA, Popoff IJ, Gaarde WA, Witchell D, Murray SF, Dean NM, Bhanot S, Monia BP. Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 2002; 51: 1028-34.
49. Macleod R, Crosby J, Zhao C, Gao D, May C, Zhang H, Lowenberg EC, Levi M, Monia BP. Pharmacological characterization and structure activity relationship of FXI antisense oligonucleotides in cynomolgus monkeys. ASH Annual Meeting Abstracts 2009; Poster Board II-78.